| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $241,198,645 ) (Continued on the next page) |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK145458 | Ultrasound Imaging Biomarkers of Crohn's Disease | 000 | 1 | NIH | 7/28/2026 | $694,443 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21AG097887 | Real world impact of glucagon-like peptide receptor agonist (GLP-1 RA) use on older adults | 000 | 1 | NIH | 3/13/2026 | $443,850 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AI195557 | Understanding iPSC reprogramming using single cycle Measles vector | 000 | 1 | NIH | 7/14/2026 | $795,316 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK143945 | Cholangiocyte Pathobiology in Cholestatic Liver Disease | 000 | 1 | NIH | 7/22/2026 | $671,966 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U01CA299909 | Prospective Detection and Monitoring of NF1 peripheral nerve sheath tumors using cell-free DNA | 000 | 1 | NIH | 6/11/2026 | $688,661 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | UG3DE035059 | Comprehensive Periodontal Therapy to Improve Oral and Cardiometabolic Health in Prediabetes | 000 | 1 | NIH | 8/14/2026 | $575,803 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG094714 | Impact of menopause on blood pressure regulation during exercise | 000 | 1 | NIH | 8/4/2026 | $678,987 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R35GM161172 | Post-Transcriptional Regulations in Stem Cell Fate Decisions | 000 | 1 | NIH | 8/14/2026 | $443,850 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA315861 | Individualized DNA junctions for glioma response assessment via longitudinal liquid biopsies | 000 | 1 | NIH | 7/24/2026 | $565,423 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL176479 | Quantitative and longitudinal assessment of diffuse pulmonary parenchymal disease using lung ultrasound surface wave elastography | 001 | 1 | NIH | 7/2/2026 | -$661,884 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL176479 | Quantitative and longitudinal assessment of diffuse pulmonary parenchymal disease using lung ultrasound surface wave elastography | 001 | 1 | NIH | 7/2/2026 | $661,884 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL176479 | Quantitative and longitudinal assessment of diffuse pulmonary parenchymal disease using lung ultrasound surface wave elastography | 000 | 1 | NIH | 6/25/2026 | $661,884 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL185686 | HOPE: Advancing HFpEF Management Through Evidence-based Treatment Optimization and Outcome Prediction | 000 | 1 | NIH | 7/30/2026 | $801,170 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA307402 | Addressing Thyroid Cancer Overdiagnosis: AI-Driven Identification, Characterization, and Outcomes of Incidental Thyroid Nodules | 000 | 1 | NIH | 3/13/2026 | $676,067 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01NS142427 | Acute and Chronic Repercussions of Spinal Cord Stimulation following Spinal Cord Injury | 000 | 1 | NIH | 7/20/2026 | $622,784 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21AI200456 | “Targeting Phosphoglucomutase in Pneumocystis Pneumonia” | 000 | 1 | NIH | 7/13/2026 | $441,100 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21AG101515 | Time-Efficient Inspiratory Muscle Strength Training for Reducing Sympathetic Activity and Improving Sleep in Midlife Women | 000 | 1 | NIH | 6/16/2026 | $439,258 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U01AI179609 | Mitochondrial Malfunction in T Cell Aging and Tissue Inflammation | 000 | 3 | NIH | 2/9/2026 | $581,040 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL166238 | Electrochemical Catheter for Prevention of Central Line-Associated Bloodstream Infection | 000 | 4 | NIH | 2/13/2026 | $382,186 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK122948 | Lipotoxicity and Liver Inflammation | 000 | 7 | NIH | 2/12/2026 | $583,961 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK132718 | Noninvasive assessment of portal hypertension and hepatic interstitial pressure with advanced magnetic resonance elastography | 000 | 4 | NIH | 1/27/2026 | $345,420 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AG093767 | Premenopausal bilateral oophorectomy and biomarkers of Alzheimer’s and cerebrovascular diseases | 000 | 2 | NIH | 4/28/2026 | $1,702,288 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AI170535 | Characterizing the role of CSDE1 as a critical co-factor for VSV replication. | 000 | 4 | NIH | 2/18/2026 | $403,500 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA272496 | Targeting PLK1 in RAS mutant chronic myelomonocytic leukemia | 000 | 4 | NIH | 5/4/2026 | $427,131 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA265050 | New Therapuetics for Pancreatic Cancer | 000 | 5 | NIH | 4/9/2026 | $598,329 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | TL1DK147565 | Next Generation KUH Researchers (GENERATOR) Training Core | 000 | 2 | NIH | 6/11/2026 | $872,729 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL176555 | Discovering aging-associated genetic modifiers and therapies for anthracycline-induced cardiotoxicity | 001 | 2 | NIH | 5/19/2026 | $659,717 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K23MD019644 | Screening Mammography: Early Breast Cancer Detection for All at Risk | 000 | 3 | NIH | 4/17/2026 | $155,520 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | OT2OD039849 | All of Us Biobank | 001 | 1 | NIH | 7/14/2026 | $13,200,000 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R21CA302685 | Improving Treatment Sensitivity through Syk using Novel Translational Models of Uveal Melanoma | 000 | 1 | NIH | 5/14/2026 | $415,000 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | U19AG102336 | Mayo Clinic Study of Aging U19 | 000 | 1 | NIH | 8/18/2026 | $4,496,369 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA304910 | Regulation of Anti-Tumor Immunity by B7-H3 | 000 | 1 | NIH | 7/9/2026 | $651,290 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K23AR086105 | Upper respiratory-genetic and nasal microbiome risk factors for rheumatoid arthritis | 001 | 1 | NIH | 8/12/2026 | $0 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K23AR086105 | Upper respiratory-genetic and nasal microbiome risk factors for rheumatoid arthritis | 000 | 1 | NIH | 7/9/2026 | $175,176 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01AI195565 | Regulation of target cell survival by TBK1 and IKKe | 000 | 1 | NIH | 2/23/2026 | $624,521 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01CA300454 | Blood-based tumor and immune markers for risk stratification and monitoring treatment response in oligometastatic prostate cancer | 000 | 1 | NIH | 3/24/2026 | $667,710 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01MH143024 | SCH: Real-Time Engagement of Children for Individualizing Behavior Management with Wearables | 000 | 1 | NIH | 5/18/2026 | $301,092 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | K08CA308863 | Unraveling the Mechanisms of Cyclin D1-Induced Replication Stress and DNA Damage Repair Dependencies in Mantle Cell Lymphoma: A Path to Novel Therapeutic Strategies for High-Risk Disease | 000 | 1 | NIH | 8/6/2026 | $324,272 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL183399 | Propofol-associated Hypertriglyceridemia: a mechanistic and causal inference analysis | 000 | 1 | NIH | 8/7/2026 | $781,013 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL184127 | Thrombolysis Resistance in Acute Ischemic Stroke | 000 | 1 | NIH | 8/6/2026 | $593,663 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01DK148528 | Islet Function in Gestational Diabetes | 000 | 1 | NIH | 8/18/2026 | $569,882 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | RF1AG044615 | Respiratory Control in Old Age | 000 | 14 | NIH | 8/11/2026 | $1,230,527 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R03EB039127 | Image-Based Analysis of Dose-Dependent Radiation Effects on the Myocardium following Cardiac Radioablation Therapy | 000 | 1 | NIH | 6/23/2026 | $80,200 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F31DK146505 | Metabolism-mediated epigenetic regulation of hepatic stellate cell activation during liver fibrosis | 002 | 1 | NIH | 7/8/2026 | $576 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F31DK146505 | Metabolism-mediated epigenetic regulation of hepatic stellate cell activation during liver fibrosis | 001 | 1 | NIH | 3/31/2026 | $0 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01EB039412 | Charge-sharing-correction for clinical multi-energy CT: Practical implementation on a whole-body photon-counting-detector CT scanner | 000 | 1 | NIH | 6/30/2026 | $620,179 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F31DK146505 | Metabolism-mediated epigenetic regulation of hepatic stellate cell activation during liver fibrosis | 000 | 1 | NIH | 3/31/2026 | $49,538 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | F31AI197938 | Designing Engineered Stem Cell Therapies for Immune-Mediated Demyelinating Diseases | 000 | 1 | NIH | 6/23/2026 | $50,114 |
| | 2026 | 2026 | MAYO CLINIC | 200 1ST ST SW | ROCHESTER | MN | 55905-0001 | OLMSTED | USA | R01HL188641 | CD40: a gatekeeper of natural antibody production in atherosclerosis | 000 | 1 | NIH | 8/11/2026 | $820,111 |
|
